About this Webinar:
Patient advocate Jimi Olaghere shares his lived expertise with Sickle Cell Disease (SCD) and what it was like to participate in a clinical trial receiving CASGEVY, an autologous, one-time, CRISPR/Cas9-edited cellular gene therapy. Jimi highlights how the therapy changed his life, going from being unable to walk more than 6,000 feet at once to summiting Mount Kilimanjaro. His story is a testament to resilience, hope and the profound impact delivery-enabled gene editing therapies can have for patients around the world, and the life-changing work of drug developers and delivery experts.
Jimi also speaks to:
How to make therapies more accessible for patients globally
His diagnosis and treatment journey
His experience in the clinical trials
The impact of the gene therapy on his mental health
How drug manufacturers can set patients up for success
This webinar is brought to you by PODD®:
Partnership Opportunities in Drug Delivery (PODD®) is committed to upholding its tradition of combining partnering, access to cutting-edge business and scientific content in the field of drug delivery, with loyal support from a top notch speaking faculty. Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, and small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations.
The PODD 2026 Conference is scheduled for October 29-30 at the Sheraton Boston.
Moderators
Speakers
